Citation Impact
Citing Papers
Microbiota in health and diseases
2022 Standout
Triple-negative breast cancer molecular subtyping and treatment progress
2020 Standout
Triple-Negative Breast Cancer
2017
Non-anthracycline-containing docetaxel and cyclophosphamide regimen is associated with sustained worse outcome compared with docetaxel, anthracycline and cyclophosphamide in neoadjuvant treatment of triple negative and HER2-positive breast cancer patients: updated follow-up data from NATT study
2016
Mitochondria and Reactive Oxygen Species in Aging and Age-Related Diseases
2018
Tumorigenic bacteria in colorectal cancer: mechanisms and treatments
2021
<p>Reactive Oxygen Species: Drivers of Physiological and Pathological Processes</p>
2020 Standout
Curcumin and cancer stem cells: curcumin has asymmetrical effects on cancer and normal stem cells.
2015
Carbon-based nanomaterials for targeted cancer nanotherapy: recent trends and future prospects
2021
Breast Cancer Statistics, 2022
2022 Standout
Traditional Chinese medicine as a cancer treatment: Modern perspectives of ancient but advanced science
2019 Standout
National trends in contralateral prophylactic mastectomy in women with locally advanced breast cancer
2018
Synthesis and antiproliferative studies of curcumin pyrazole derivatives
2016
Plant Secondary Metabolites as Anticancer Agents: Successes in Clinical Trials and Therapeutic Application
2018 Standout
Graphene family, and their hybrid structures for electromagnetic interference shielding applications: Recent trends and prospects
2021 Standout
Works of Kejin Wu being referenced
Targeting ANXA1 abrogates Treg-mediated immune suppression in triple-negative breast cancer
2020
Oxygen-Carbon Nanotubes as a Chemotherapy Sensitizer for Paclitaxel in Breast Cancer Treatment
2014
Curcumin induces apoptosis in gallbladder carcinoma cell line GBC-SD cells
2013
A standard mastectomy should not be the only recommended breast surgical treatment for non-metastatic inflammatory breast cancer: A large population-based study in the Surveillance, Epidemiology, and End Results database 18
2017
Superior outcome after neoadjuvant chemotherapy with docetaxel, anthracycline, and cyclophosphamide versus docetaxel plus cyclophosphamide: results from the NATT trial in triple negative or HER2 positive breast cancer
2013